Entering the U.S. generics market

Korean biopharmaceutical Celltrion aims to strengthen its position as a global generics pharmaceutical company and enter the U.S. and global tender markets by developing generics and incrementally modified drugs (IMDs). The company did not have the reliable data needed to make accurate decisions and spent considerable time and expense gathering and analyzing data from multiple sources. To overcome this challenge, it turned to Cortellis Generics Intelligence™ because of its timely, reliable and independently validated content.